Patients w/ CV diseases & hypotension; severe peripheral circulatory disturbance/disorders; mild/moderate COPD. Resp reactions in patients w/ asthma. Patients subject to spontaneous hypoglycaemia or patients w/ labile diabetes. May potentiate muscle weakness consistent w/ certain myasthenic symptoms. May induce dryness of eyes. Choroidal detachment. Patients already receiving a systemic β-blocking medicinal product. May block systemic β-agonist effects eg, of adrenaline. May mask the signs of hyperthyroidism. Patients w/ history of atopy or severe anaphylactic reaction to a variety of allergens. Use of 2 local prostaglandins is not recommended. Ocular effects eg, gradual change in the eye colour, periorbital & lid changes, change in eyelashes, slight enlargement of the palpebral fissure. Aphakic patients, pseudophakic patients w/ a torn posterior lens capsule or anterior chamber lenses, or patients w/ known risk factors for cystoid macular oedema; patients w/ known predisposing risk factors for iritis/uveitis, & in patients w/ active intraocular inflammation. Contains propylene glycol & polyoxyethylene hydrogenated castor oil 40. Remove contact lenses prior to application & wait 15 min after instillation of the dose before reinsertion. If blurred vision occurs at instillation, wait until the vision clears before driving or using machines. Must not be used in women of childbearing potential unless adequate contraceptive measures are in place. Pregnant women or women attempting to become pregnant should avoid direct exposure to the contents of DuoTrav. Should not be used during pregnancy unless clearly necessary. Not recommended in breastfeeding women.